Therapeutic Candidate Portfolio: Proprietary and Powerful Drug Candidates for the Treatment of Blood and Solid Tumor Malignancies
Aptevo Therapeutics is advancing a powerful pipeline of bispecific and trispecific immunotherapies designed to meet urgent, unmet needs in cancer care and improve patient outcomes.
To achieve this goal, the Company engineers novel mechanisms of action that are purpose-built for safety and seamless combinability with current standards of care and emerging therapies. Using its proprietary platforms, Aptevo engages multiple immune pathways—including redirected T-cell cytotoxicity (RTCC), T-cell co-stimulation, and other critical biological circuits—to drive the next generation of cancer and autoimmune treatments.
